A compendium of critical appraisals in Intensive Care Medicine research and related specialties
A category to collect all the summaries, so that they can be used in menus and widgets. Please don’t expand this – “Specialties” and “Special Topics” have been created as a custom category sets for the clinical topics.
Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial Anderson et al. JAMA 2021. doi:10.1001/jama.2021.16628 Clinical Question In adult patients suffering an in-hospital cardiac arrest (IHCA) does the use of vasopressin and methylprednisolone compared to a placebo result in increased rates of return of spontaneous circulation (ROSC)? […]
Continue reading »
In hypoxic African children (oxygen saturations of between 80 and 91%) with pneumonia, does oxygen therapy reduce mortality when compared with a permissive hypoxia (no oxygen) strategy?
In severely hypoxic children (oxygen saturations less than 80%), does high-flow nasal therapy reduce mortality when compared with low-flow oxygen therapy?
In patients who present with an acute STEMI and are referred for percutaneous coronary intervention (PCI), does colchicine in comparsion with placebo reduce myocardial injury?
Continue reading »
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »
In mechanically ventilated patients with acute hypoxaemic respiratory failure, does lowering tidal volume using extracorporeal carbon dioxide removal, compared with conventional low tidal volume ventilation, improve day 90 all-cause mortality?
Continue reading »
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »
In hospitalised adult patient with COVID-19, does baricitinib compared with placebo decrease a composite outcome of progression of illness and mortality?
Continue reading »
Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation Desch S et al. NEJM 2021. DOI: 10.1056/NEJMoa2101909 Clinical Question In adults > 30 years old suffering out-of-hospital cardiac arrest (OOHCA) without ST elevation on their ECG does routine immediate coronary angiography compared to a delayed or selective approach to coronary angiography improve 30-day all-cause mortality? Background The DISCO pilot study showed […]
Continue reading »
Milrinone as compared with Dobutamine in the Treatment of Cardiogenic Shock Matthew. N Engl J Med 2021; 385:516-525, doi: 10.1056/NEJMoa2026845 Clinical Question In patients with cardiogenic shock, does milrinone as compared with dobutamine improve the composite outcome of in-hospital death, resuscitated cardiac arrest, receipt of cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, cerebrovascular event or renal replacement therapy? […]
Continue reading »
In hospitalised patients with COVID-19 requiring >40% FiO2 to achieve SaO2>94%, does the use of continuous positive airway pressure (CPAP) or high flow nasal oxygen (HFNO) compared with conventional O2 therapy (COT) reduce the incidence of tracheal intubation or death within 30 days?
Continue reading »